Mender I, Siteni S, Barron S, Flusche A.M, Kubota N, Yu C, Cornelius C, Tedone E, Maziveyi M, Grichuk A, et al. Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. Molecular cancer therapeutics. 2023. 22. 6. 737-750
Saito Y, Yin D, Kubota N, Wang X, Filliol A, Remotti H, Nair A, Fazlollahi L, Hoshida Y, Tabas I, et al. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology. 2023. 164. 7. 1279-1292
Wang Z, Zhu S, Jia Y, Wang Y, Kubota N, Fujiwara N, Gordillo R, Lewis C, Zhu M, Sharma T, et al. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease. Cell. 2023. 186. 9. 1968-1984.e20
Wang X, He Q, Zhou C, Xu Y, Liu D, Fujiwara N, Kubota N, Click A, Henderson P, Vancil J, et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity. 2023. 56. 1. 58-77.e11
Fujiwara N, Kubota N, Zhu S, Nakagawa S, Baba H, Hoshida Y. Disseminative Recurrence Signature for Hepatocellular Carcinoma From Nonalcoholic Fatty Liver Disease. Gastro hep advances. 2023. 2. 5. 681-683